Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells
- PMID: 39300319
- PMCID: PMC11528031
- DOI: 10.1038/s41423-024-01215-0
Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells
Abstract
Hepatocellular carcinoma (HCC) is a highly malignant tumor with significant global health implications. The role of CD4+ T cells, particularly conventional CD4+ T cells (Tconvs), in HCC progression remains unexplored. Furthermore, epigenetic factors are crucial in immune regulation, yet their specific role in HCC-infiltrating Tconv cells remains elusive. This study elucidates the role of MATR3, an epigenetic regulator, in modulating Tconv activity and immune evasion within the HCC microenvironment. Reanalysis of the scRNA-seq data revealed that early activation of CD4+ T cells is crucial for establishing an antitumor immune response. In vivo and in vitro experiments revealed that Tconv enhances cDC1-induced CD8+ T-cell activation. Screening identified MATR3 as a critical regulator of Tconv function, which is necessary for antitumour activity but harmful when overexpressed. Excessive MATR3 expression exacerbates Tconv exhaustion and impairs function by recruiting the SWI/SNF complex to relax chromatin in the TOX promoter region, leading to aberrant transcriptional changes. In summary, MATR3 is an HCC-specific epigenetic checkpoint that bidirectionally regulates Tconv antitumour immunity, suggesting new therapeutic strategies targeting epigenetic regulators to enhance antitumour immunity in HCC.
Keywords: ARID1A; Exhaustion; MATR3; TOX; Tconv.
© 2024. The Author(s), under exclusive licence to CSI and USTC.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity.J Hepatol. 2025 Aug;83(2):397-410. doi: 10.1016/j.jhep.2025.01.027. Epub 2025 Jan 30. J Hepatol. 2025. PMID: 39892819
-
Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma.Apoptosis. 2025 Feb;30(1-2):55-68. doi: 10.1007/s10495-024-02019-3. Epub 2024 Sep 26. Apoptosis. 2025. PMID: 39327353 Free PMC article.
-
HLA-DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T-Cell Exhaustion in HBV-Associated Hepatocellular Carcinoma.Adv Sci (Weinh). 2025 Aug;12(30):e02979. doi: 10.1002/advs.202502979. Epub 2025 Jun 4. Adv Sci (Weinh). 2025. PMID: 40464412 Free PMC article.
-
The mechanisms and clinical significance of CD8+ T cell exhaustion in anti-tumor immunity.Cancer Biol Med. 2025 Jun 10;22(5):460-80. doi: 10.20892/j.issn.2095-3941.2024.0628. Cancer Biol Med. 2025. PMID: 40492696 Free PMC article. Review.
-
Nonalcoholic fatty liver disease and hepatocellular carcinoma.Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23. Metabolism. 2016. PMID: 26907206
Cited by
-
T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells.Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):10007-10024. doi: 10.1007/s00210-025-04035-9. Epub 2025 Mar 18. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40100377 Review.
-
Chromatin remodeling in lymphocytic function and fate: the multifaceted roles of SWI/SNF complex.Front Immunol. 2025 Apr 24;16:1575857. doi: 10.3389/fimmu.2025.1575857. eCollection 2025. Front Immunol. 2025. PMID: 40342423 Free PMC article. Review.
-
Investigation of mitochondrial DNA methylation-related prognostic biomarkers in hepatocellular carcinoma using The Cancer Genome Atlas (TCGA) database.Transl Cancer Res. 2025 Mar 30;14(3):2095-2112. doi: 10.21037/tcr-2025-546. Epub 2025 Mar 27. Transl Cancer Res. 2025. PMID: 40224972 Free PMC article.
-
Chromatin remodeling and cancer: the critical influence of the SWI/SNF complex.Epigenetics Chromatin. 2025 Apr 23;18(1):22. doi: 10.1186/s13072-025-00590-w. Epigenetics Chromatin. 2025. PMID: 40269969 Free PMC article. Review.
-
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy.Cell Mol Immunol. 2025 Jun 11. doi: 10.1038/s41423-025-01308-4. Online ahead of print. Cell Mol Immunol. 2025. PMID: 40500404 Review.
References
-
- Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomized, open-label, international phase 3 study. Lancet. 2023;402:1133–46. - PubMed
-
- Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 2022;185:4049–66. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials